“With some investors now looking to take on a bit more risk, they are turning to the ultimate risk/reward plays: biotech stocks,” notes the author of today’s article. One of the few major catalysts for biotech stocks is regulatory approval – and the author highlights “three compelling biotech stocks with upcoming Prescription Drug User Fee Act (PDUFA) dates, the deadline…
If you want to earn just “average” gains in the post-coronavirus economy, invest in broad index funds. But if you want better-than-average returns, stock and non-broad-based ETF picking will be the way to go, argues the author of today’s article. Just what are the many major shifts – from privacy rights to education to biotechnology – that the economy will…
An estimated 70 million Americans suffer from insomnia – and that number is undoubtedly climbing as the country deals with the stress and anxiety associated with the COVID-19 pandemic. While many for whom sleep proves to be elusive turn to prescription medications and over-the-counter sleep aids, there’s evidence that adults are increasingly turning to cannabis to help promote sleep –…
Biotech stocks have weathered the coronavirus selloff pretty well on the whole – and today’s article notes that “Several biotechs have delivered solid gains in the midst of the overall stock market plunge.” For three top biotech stock picks that have been beating the market and that still have lots of room to run from here – including one “oddball”…
The trader behind the strategy highlighted in today’s article is typically not a day trader, but in what he acknowledges are “definitely not normal times” for the stock market right now, he no longer holds positions overnight, arguing that has become too risky. Instead, he has been employing a strategy that has proven to be profitable – even when he’s…
After spending the last few months “laser-focused” on coronavirus biotech plays, the author of today’s article has begun to look elsewhere for profit-making opportunities as biotech stocks have become increasingly crowded. He is now focusing on “stocks positioned to prosper in these times of social isolation” – and he shares his list of top penny stocks right now, which he…
While the Volatility Index (or VIX), a popular measure of implied market volatility, is not as high as it was recently, it is still well above normal levels – and the author of today’s article highlights a trade to consider to profit from this highly volatile trading environment in which “options’ premium is all plumped up and ready for feasting…
In regards to market activity over the last several weeks, the author of today’s article acknowledges that “The past month has been pretty extraordinary.” And that’s probably putting it mildly. However, while we are entering what may be the most difficult weeks of the coronavirus crisis, he notes that “there are signs that the market is starting to act more…
March 2020 was not the worst-performing month in stock market history, but it was the craziest month in stock market history, according to the author of today’s article. That is, if crazy is defined by monthly market volatility. In fact, he notes that in terms of one particular measure of volatility, “March 2020 wasn’t just a little crazier than the…
While analysts at Goldman Sachs believe that the S&P 500 will rise to 3,000 by the end of the year, they also caution that, despite the market having rallied in recent days, more pain lies ahead in the coming weeks and that the market has not hit its coronavirus-induced bottom yet. When can market participants feel confident that the market…